Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Jiefeng Tong, Songfu Jiang, Qian Luo, Shanhu Qian, Guifang Ouyang, Yanli Lai, Huifang Jiang, Yuxia Jiang, Hui Zeng, Baodong Ye, Wei Jiang, Wenbin Qian

Blood (2024) 144 (Supplement 1): 7762.

https://doi.org/10.1182/blood-2024-204522

Published: 2024

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Ryan C. Lynch, Abraham Avigdor, Matthew S McKinney, Shankara Paneesha, Björn Wahlin, John S Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J DeMarini, Wei Jiang, Marek Trněný

Blood (2021) 138 (Supplement 1): 813.

https://doi.org/10.1182/blood-2021-147918

Published: 2021

Journal Articles

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Wei Jiang, Gaurav Sutrave, Selmir Avdic, Leighton Edward Clancy, Shafqat Inam, Elissa Atkins, Caroline M Bateman, Adrian Gabriel Selim, Vicki Antonenas, Janine Street, Renee Simms, Peter J. Shaw, David Ritchie, Emily Blyth, David J Gottlieb

Blood (2021) 138 (Supplement 1): 255.

https://doi.org/10.1182/blood-2021-152396

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Amitkumar Mehta, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane, Guillermo Rodriguez, Michal Taszner, Parameswaran Venugopal, Vittorio Ruggero Zilioli, Fred Zheng, Douglas J DeMarini, Wei Jiang, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 382.

https://doi.org/10.1182/blood-2021-147867

Published: 2021

Journal Articles

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac -modified CD19 CAR T cells

Blood (2021) 138 (16): 1504–1509.

https://doi.org/10.1182/blood.2021010813

Published: 2021

Includes: Supplemental data

Journal Articles

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Wei Jiang, MBBS, M Clin MD FRACP, FRCPA, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Peter J. Shaw, MA,FRACP, Leighton Edward Clancy, BSc, PhD, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Abir Bhattacharyya, MBBS, FRACP, FRCPA, Elissa Atkins, RN, Selmir Avdic, PhD, Gaurav Sutrave, MBBS, FRACP, FRCPA, Janine Street, BSc MSc (Hons), David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-143136

Published: 2020

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Ryan C. Lynch, MD, Shankara Paneesha, MD, Abraham Avigdor, MD, Matthew S McKinney, Björn E Wahlin, MD PhD, John S Hrom, David Belada, MD PhD, Miguel Canales, David Cunningham, MD FRCP, FMedSci, Liliana Devizzi, Nicholas Morley, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Marek Trněný, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134869

Published: 2020

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Pier Luigi Zinzani, MD, Vincent Delwail, Shankara Paneesha, MD, Simon Rule, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Ana Marin-Niebla, MD PhD, Gilles Salles, MD PhD, Juan-Manuel Sancho, MD PhD, Vibeke Vergote, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Amitkumar Mehta, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-134609

Published: 2020

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Amitkumar Mehta, MD, Marek Trněný, MD, Jan Walewski, MD, Vincent Ribrag, MD, Caroline Dartigeas, MD, Jacob Haaber Christensen, MD PhD, Fabrizio Pane, MD, Guillermo Rodríguez, MD, Michal Taszner, MD, Parameswaran Venugopal, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134872

Published: 2020

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes

Wei Jiang, Szu-Hee Lee

Blood (2018) 132 (21): 2314.

https://doi.org/10.1182/blood-2018-08-870675

Published: 2018

Journal Articles

Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin

Blood (2018) 131 (12): 1325–1336.

https://doi.org/10.1182/blood-2017-07-794875

Published: 2018

Includes: Supplemental data

Journal Articles

c-Myc controls the development of CD8αα TCRαβ intestinal intraepithelial lymphocytes from thymic precursors by regulating IL-15–dependent survival

Wei Jiang, Isabel Ferrero, Elisa Laurenti, Andreas Trumpp, H. Robson MacDonald

Blood (2010) 115 (22): 4431–4438.

https://doi.org/10.1182/blood-2009-11-254698

Published: 2010

Journal Articles

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation

Nicholas T. Funderburg, Elizabeth Mayne, Scott F. Sieg, Robert Asaad, Wei Jiang, Magdalena Kalinowska, Angel A. Luciano, Wendy Stevens, Benigno Rodriguez, Jason M. Brenchley, Daniel C. Douek, Michael M. Lederman

Blood (2010) 115 (2): 161–167.

https://doi.org/10.1182/blood-2009-03-210179

Published: 2010

Journal Articles

Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression

Gareth A. D. Hardy, Scott F. Sieg, Benigno Rodriguez, Wei Jiang, Robert Asaad, Michael M. Lederman, Clifford V. Harding

Blood (2009) 113 (22): 5497–5505.

https://doi.org/10.1182/blood-2008-11-190231

Published: 2009

Journal Articles

Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells

Pengbo Zhang, Jian Li, Zhijia Tan, Chengyan Wang, Ting Liu, Lin Chen, Jun Yong, Wei Jiang, Xiaomeng Sun, Liying Du, Mingxiao Ding, Hongkui Deng

Blood (2008) 111 (4): 1933–1941.

https://doi.org/10.1182/blood-2007-02-074120

Published: 2008

NARROW

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac -modified CD19 CAR T cells

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes

Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin

c-Myc controls the development of CD8αα TCRαβ intestinal intraepithelial lymphocytes from thymic precursors by regulating IL-15–dependent survival

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation

Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression

Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only